Norges Bank Incyte Corp Transaction History

Norges Bank

  • $772 Billion
  • Q2 2025

A detailed history of Norges Bank transactions in Incyte Corp stock. As of the latest transaction made, Norges Bank holds 1,421,080 shares of INCY stock, worth $116 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,421,080
Holding current value
$116 Million
% of portfolio
0.01%

Shares

52 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025
BUY
$55.17 - $71.22 $78.4 Million - $101 Million
1,421,080 New
1,421,080 $96.8 Million
Q4 2024

Feb 12, 2025
BUY
$65.08 - $83.38 $115 Million - $147 Million
1,764,725 New
1,764,725 $122 Million
Q2 2024

Aug 14, 2024
BUY
$51.18 - $63.75 $109 Million - $135 Million
2,124,167 New
2,124,167 $129 Million
Q1 2024

May 14, 2025
BUY
$56.55 - $66.59 $116 Million - $137 Million
2,052,072 New
2,052,072 $117 Million
Q4 2023

Feb 09, 2024
BUY
$52.16 - $64.19 $102 Million - $126 Million
1,962,937 New
1,962,937 $123 Million
Q3 2023

Nov 13, 2024
BUY
$57.77 - $65.93 $108 Million - $123 Million
1,866,694 New
1,866,694 $108 Million
Q3 2023

Nov 13, 2023
SELL
$57.77 - $65.93 $83 Million - $94.8 Million
-1,437,396 Closed
0 $0
Q2 2023

Aug 14, 2024
SELL
$60.95 - $75.51 $16.1 Million - $20 Million
-264,751 Reduced 12.46%
1,859,416 $116 Million
Q2 2023

Aug 14, 2023
SELL
$60.95 - $75.51 $84 Million - $104 Million
-1,377,731 Closed
0 $0
Q1 2023

May 15, 2024
BUY
$70.23 - $86.01 $127 Million - $156 Million
1,814,931 New
1,814,931 $131 Million
Q4 2022

Feb 14, 2023
BUY
$67.18 - $84.11 $105 Million - $131 Million
1,558,376 New
1,558,376 $125 Million
Q3 2022

Nov 13, 2023
BUY
$66.18 - $82.86 $95.1 Million - $119 Million
1,437,396 New
1,437,396 $95.8 Million
Q2 2022

Aug 14, 2023
BUY
$66.18 - $83.18 $91.2 Million - $115 Million
1,377,731 New
1,377,731 $105 Million
Q1 2022

May 12, 2023
BUY
$66.02 - $79.71 $12.6 Million - $15.3 Million
191,491 Added 12.29%
1,749,867 $139 Million
Q1 2022

May 09, 2022
SELL
$66.02 - $79.71 $111 Million - $134 Million
-1,679,539 Closed
0 $0
Q4 2021

Mar 09, 2022
BUY
$63.34 - $74.11 $106 Million - $124 Million
1,679,539 New
1,679,539 $123 Million
Q3 2021

Nov 14, 2022
BUY
$68.67 - $84.02 $113 Million - $138 Million
1,646,502 New
1,646,502 $113 Million
Q3 2021

Nov 05, 2021
SELL
$68.67 - $84.02 $115 Million - $141 Million
-1,680,749 Closed
0 $0
Q2 2021

Aug 15, 2022
BUY
$79.87 - $87.53 $134 Million - $147 Million
1,680,749 New
1,680,749 $141 Million
Q2 2021

Aug 10, 2021
SELL
$79.87 - $87.53 $144 Million - $158 Million
-1,804,590 Closed
0 $0
Q1 2021

May 09, 2022
BUY
$76.02 - $100.5 $137 Million - $181 Million
1,804,590 New
1,804,590 $147 Million
Q1 2021

May 07, 2021
SELL
$76.02 - $100.5 $143 Million - $189 Million
-1,877,425 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$80.74 - $97.7 $152 Million - $183 Million
1,877,425 New
1,877,425 $163 Million
Q4 2020

Feb 10, 2021
SELL
$80.74 - $97.7 $152 Million - $183 Million
-1,876,840 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$85.07 - $109.69 $160 Million - $206 Million
1,876,840 New
1,876,840 $168 Million
Q3 2020

Nov 10, 2020
SELL
$85.07 - $109.69 $145 Million - $187 Million
-1,707,916 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$74.18 - $108.93 $127 Million - $186 Million
1,707,916 New
1,707,916 $178 Million
Q2 2020

Aug 07, 2020
SELL
$74.18 - $108.93 $141 Million - $207 Million
-1,901,835 Closed
0 $0
Q1 2020

May 07, 2021
BUY
$63.18 - $85.97 $120 Million - $164 Million
1,901,835 New
1,901,835 $139 Million
Q1 2020

May 08, 2020
SELL
$63.18 - $85.97 $129 Million - $176 Million
-2,049,032 Closed
0 $0
Q4 2019

Mar 03, 2020
BUY
$73.04 - $95.72 $150 Million - $196 Million
2,049,032 New
2,049,032 $179 Million
Q4 2019

Feb 12, 2020
SELL
$73.04 - $95.72 $154 Million - $202 Million
-2,107,947 Closed
0 $0
Q3 2019

Nov 13, 2020
BUY
$72.82 - $86.52 $154 Million - $182 Million
2,107,947 New
2,107,947 $156 Million
Q3 2019

Nov 08, 2019
SELL
$72.82 - $86.52 $151 Million - $180 Million
-2,079,402 Closed
0 $0
Q2 2019

Aug 13, 2020
BUY
$73.52 - $88.7 $153 Million - $184 Million
2,079,402 New
2,079,402 $177 Million
Q2 2019

Aug 09, 2019
SELL
$73.52 - $88.7 $162 Million - $196 Million
-2,204,545 Closed
0 $0
Q1 2019

May 11, 2020
SELL
$63.56 - $88.17 $46.4 Million - $64.4 Million
-730,352 Reduced 24.89%
2,204,545 $190 Million
Q4 2018

Mar 04, 2019
BUY
$58.5 - $69.94 $172 Million - $205 Million
2,934,897 New
2,934,897 $187 Million
Q4 2018

Feb 08, 2019
SELL
$58.5 - $69.94 $134 Million - $160 Million
-2,294,400 Closed
0 $0
Q3 2018

Nov 12, 2019
BUY
$61.75 - $74.23 $142 Million - $170 Million
2,294,400 New
2,294,400 $158 Million
Q3 2018

Nov 09, 2018
SELL
$61.75 - $74.23 $151 Million - $181 Million
-2,441,296 Closed
0 $0
Q2 2018

Aug 12, 2019
BUY
$60.85 - $83.98 $149 Million - $205 Million
2,441,296 New
2,441,296 $164 Million
Q2 2018

Jul 23, 2018
SELL
$60.85 - $83.98 $143 Million - $198 Million
-2,356,344 Closed
0 $0
Q1 2018

May 15, 2019
BUY
$83.06 - $100.98 $196 Million - $238 Million
2,356,344 New
2,356,344 $196 Million
Q1 2018

May 09, 2018
SELL
$83.06 - $100.98 $190 Million - $231 Million
-2,283,505 Closed
0 $0
Q4 2017

Mar 05, 2018
BUY
$93.56 - $116.6 $214 Million - $266 Million
2,283,505 New
2,283,505 $216 Million
Q4 2017

Feb 09, 2018
SELL
$93.56 - $116.6 $195 Million - $243 Million
-2,085,712 Closed
0 $0
Q3 2017

Nov 13, 2018
BUY
$109.15 - $138.27 $228 Million - $288 Million
2,085,712 New
2,085,712 $243 Million
Q3 2017

Nov 07, 2017
SELL
$109.15 - $138.27 $229 Million - $291 Million
-2,101,531 Closed
0 $0
Q2 2017

Jul 24, 2018
BUY
N/A
497,517 Added 31.02%
2,101,531 $265 Million
Q1 2017

May 11, 2018
BUY
N/A
85,500 Added 5.63%
1,604,014 $214 Million
Q3 2016

Nov 13, 2017
BUY
N/A
1,518,514
1,518,514 $0

Others Institutions Holding INCY

# of Institutions
724
Shares Held
203M
Call Options Held
560K
Put Options Held
246K
View Full List

About INCYTE CORP

INCY Quotes by TradingView
  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $18.2B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email